AnaptysBio has transformed into a royalty management company centered on Jemperli, an oncology drug commercialized by GSK. The company now operates with minimal costs, targeting a 95% EBIT margin and holding over $140 million in net cash, eliminating previous R&D expenses. Jemperli royalties are expected to increase with sales, and after settling an obligation to Sagard by mid-2027, AnaptysBio will benefit from high-margin, growing royalty streams. Positive trial data and potential label expansions for Jemperli, along with a $100 million share buyback plan, support the company's new focus despite some risks related to litigation and revenue concentration.
OMODA & JAECOO launched the OMODA 4 SUV in Southeast Asia at the OMODA SUPER AI NIGHT event in Jakarta, showcasing its AI-powered cockpit technology integrated with ByteDance Seed large language model. The event highlighted the brand's strategy to ex...
Venice Token (VVV) has seen its price fall by 11% after failing to break through a key Fibonacci resistance zone, leading to a sharp downward reversal. Market activity is cooling, with open interest dropping 17%, signaling traders are closing positio...
Hope Bancorp reported strong Q2 2026 results, surpassing revenue and adjusted EPS expectations and shifting from a loss to a profit. The bank's net interest margin improved to 2.96%, with growth in deposits and loans, and a significant rebound in non...
FLUENT Corp shareholders have approved a special resolution for an all-stock acquisition by Vireo Growth Inc. Under the plan, Vireo will acquire all FLUENT shares in exchange for subordinate voting shares of Vireo. The deal, approved by over 82% of v...
Travelzoo reported poor Q2 financial results with negative revenue growth and declining profit margins. The company's shift to a members-only model is challenged by strong competition from other online travel agencies' loyalty programs, reducing its ...
